BioCentury
ARTICLE | Clinical News

AUT00063: Phase IIa started

December 8, 2014 8:00 AM UTC

Autifony began the double-blind, placebo-controlled, U.K. Phase IIa QUIET-1 trial to evaluate 800 mg oral AUT00063 once daily for 28 days in about 152 patients. ...